Schaub, Christina and Kebir, Sied and Junold, Nina and Hattingen, Elke and Schaefer, Niklas and Steinbach, Joachim P. and Weyerbrock, Astrid and Hau, Peter and Goldbrunner, Roland and Niessen, Michael and Mack, Frederic and Stuplich, Moritz and Tzaridis, Theophilos and Baehr, Oliver and Kortmann, Rolf-Dieter and Schlegel, Uwe and Schmidt-Graf, Friederike and Rohde, Veit and Braun, Christian and Haenel, Mathias and Sabel, Michael and Gerlach, Ruediger and Krex, Dietmar and Belka, Claus and Vatter, Hartmut and Proescholdt, Martin and Herrlinger, Ulrich and Glas, Martin (2018) Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 144 (8). pp. 1581-1589. ISSN 0171-5216, 1432-1335
Full text not available from this repository. (Request a copy)Abstract
We evaluated patterns of tumor growth in patients with newly diagnosed MGMT-non-methylated glioblastoma who were assigned to undergo radiotherapy in conjunction with bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ) within the randomized phase II GLARIUS trial. In 142 patients (94 BEV/IRI, 48 TMZ), we reviewed magnetic resonance imaging scans at baseline and first tumor recurrence. Based on contrast-enhanced T1-weighted and fluid-attenuated inversion recovery images, we assessed tumor growth patterns and tumor invasiveness. Tumor growth patterns were classified as either multifocal or local at baseline and recurrence; at first recurrence, we additionally assessed whether distant lesions appeared. Invasiveness was determined as either diffuse or non-diffuse. Associations with treatment arms were calculated using Fisher's exact test. At baseline, 115 of 142 evaluable patients (81%) had a locally confined tumor. Between treatment arms, there was no significant difference in the fraction of tumors that changed from an initially local tumor growth pattern to a multifocal pattern (12 and 13%, p = 0.55). Distant lesions appeared in 17% (BEV/IRI) and 13% (TMZ) of patients (p = 0.69). 15% of patients in the BEV/IRI arm and 8% in the TMZ arm developed a diffuse growth pattern from an initially non-diffuse pattern (p = 0.42). The tumor growth and invasiveness patterns do not differ between BEV/IRI and TMZ-treated MGMT-non-methylated glioblastoma patients in the GLARIUS trial. BEV/IRI was not associated with an increased rate of multifocal, distant, or highly invasive tumors at the time of recurrence.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | NEWLY-DIAGNOSED GLIOBLASTOMA; BEVACIZUMAB PLUS IRINOTECAN; RECURRENT GLIOBLASTOMA; ANTIANGIOGENIC THERAPY; MALIGNANT GLIOMAS; FACTOR RECEPTOR-2; PHASE-III; IN-VIVO; PROGRESSION; SURVIVAL; Bevacizumab; Newly diagnosed MGMT-non-methylated glioblastoma; MRI tumor growth patterns; Progression patterns |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 04 Mar 2020 08:31 |
| Last Modified: | 04 Mar 2020 08:31 |
| URI: | https://pred.uni-regensburg.de/id/eprint/14185 |
Actions (login required)
 |
View Item |
